Sheffield,UK, April 2024: SynGenSys, a biotechnology company designingsynthetic gene promoter systems to address critical bottlenecks in biopharmamanufacturing and enhance cell and gene therapy development, today announced theintroduction of CHO.SET®, a library of novel, patentable and tested promotersdesigned in silico to allow tuneable gene expression, to enhancebiomanufacturing processes.
CHO.SET,designed using SynGenSys’ proprietary informatics and design workflow, is alibrary of novel, patentable, fully tested synthetic promoters. The range ofoff-the-shelf promoters has been designed to deliver exceptional yieldimprovements for standard, multi-component, and difficult-to express (DTE)proteins. These promoters enhance production efficiency and quality, offering greateryield and stability through the careful combination of proximal promoter elements.Turnaround time is also reduced, with promoter selection to delivery of leadand backup expression vectors completed within 11 weeks.
Professor David James, Co-founderand Chief Technology Officer, SynGenSys, said: “The rate ofrecombinant gene transcription mediated by commonly used natural promoters(such as viral CMV) limits CHO cell factory productivity. This in turn limitsprocess yield for these high-value products. There is therefore a clear need fora solution, which we feel our new CHO:SET library provides to the biopharmaindustry.”
